{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreih32smy3utrg5opljhxvhdddrtvfngvmyv6ow7i7ygmfgp7eoqudm",
    "uri": "at://did:plc:bddzhg3qqlwimkvjsgxcz5wh/app.bsky.feed.post/3mp7e25h7tf32"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreiakoicp42mwgz7df4ajxppo4fgel4jwijvk7fdwdx636nct4eryxm"
    },
    "mimeType": "image/png",
    "size": 1542967
  },
  "path": "/2026/06/definiums-lsd-depressiondrug-sends-shares-soaring-after-breakthrough-trialresults/?utm_source=rss&utm_medium=rss&utm_campaign=definiums-lsd-depressiondrug-sends-shares-soaring-after-breakthrough-trialresults",
  "publishedAt": "2026-06-26T16:04:15.000Z",
  "site": "https://www.edmtunes.com",
  "tags": [
    "Music News",
    "Arrpita",
    "definium",
    "edmtunes news",
    "lsd depression drug",
    "trial",
    "Definium’s LSD Depression Drug Sends Shares Soaring After Breakthrough Trial Results",
    "EDMTunes"
  ],
  "textContent": "*Feature Image : NY Post, Reuters Definium Therapeutics just shook both biotech and mental health spaces in a big way. The company’s shares [NASDAQ: DFTX] surged more than 50% after its LSD-based depression treatment delivered strong late-stage trial results, signaling a potential shift in how we treat major depressive disorder. The drug, known as DT120, […]\n\nThe post Definium’s LSD Depression Drug Sends Shares Soaring After Breakthrough Trial Results appeared first on EDMTunes.",
  "title": "Definium’s LSD Depression Drug Sends Shares Soaring After Breakthrough Trial Results"
}